Abstract Introduction: There is growing recognition of the potential of cannabis to treat various medical conditions and symptoms, such as…
Abstract Supplementary Information: The online version contains supplementary material available at 10.1007/s00406-021-01318-z. Article type: Research Article Keywords: Clinical high risk,…
Abstract The standardization of cannabis doses is a priority for research, policy-making, clinical and harm-reduction interventions and consumer security. Scientists…
Abstract Background: Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus…
Abstract The endocannabinoid system is a complex neuronal system involved in a number of biological functions, like attention, anxiety, mood,…
Abstract Emotional dysregulation and anxiety are common in people at clinical high risk for psychosis (CHR) and are associated with…
Abstract Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of cannabis use…
Abstract Accumulating evidence points towards the antipsychotic potential of cannabidiol. However, the neurocognitive mechanisms underlying the antipsychotic effect of cannabidiol…
Abstract The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use…
Abstract The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in…